H1N1 News and Research

RSS
Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Covidien first-quarter net sales increase 5% to $2.77 billion

Covidien first-quarter net sales increase 5% to $2.77 billion

News briefs from February issue of journal Chest

News briefs from February issue of journal Chest

New study: Swine flu transmission is most intensive between children of same class

New study: Swine flu transmission is most intensive between children of same class

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

PSS World Medical third quarter consolidated earnings per diluted share increase 16.6% to $0.35

PSS World Medical third quarter consolidated earnings per diluted share increase 16.6% to $0.35

International Federation of Red Cross and Red Crescent Societies and Coca-Cola enter global partnership

International Federation of Red Cross and Red Crescent Societies and Coca-Cola enter global partnership

BMJ News examines ongoing investigation of WHO's handling of H1N1

BMJ News examines ongoing investigation of WHO's handling of H1N1

WHO Director-General expresses concern over public mistrust of vaccines

WHO Director-General expresses concern over public mistrust of vaccines

Convalescent plasma therapy may reduce mortality rate in patients with H1N1 infection: Study

Convalescent plasma therapy may reduce mortality rate in patients with H1N1 infection: Study

FDA clears Nanosphere's RV+ test for detection of respiratory viruses

FDA clears Nanosphere's RV+ test for detection of respiratory viruses

BioCryst reports positive results from peramivir Phase 3 study in influenza

BioCryst reports positive results from peramivir Phase 3 study in influenza

New research paper reveals key lessons about origins of 2009 H1N1 pandemic

New research paper reveals key lessons about origins of 2009 H1N1 pandemic

56% of respondents have still not received flu shots

56% of respondents have still not received flu shots

Antibodies produced by people who recovered from H1N1 offer clues for universal flu vaccine

Antibodies produced by people who recovered from H1N1 offer clues for universal flu vaccine

OraSure to introduce QuickFlu test for detection of type A and type B influenza

OraSure to introduce QuickFlu test for detection of type A and type B influenza

Potential single vaccine for permanent immunity to all influenza

Potential single vaccine for permanent immunity to all influenza

Air purifier helps reduce H1N1 swine flu virus on contact

Air purifier helps reduce H1N1 swine flu virus on contact

New lab-on-a-chip technology detects protein in blood less than 30 minutes

New lab-on-a-chip technology detects protein in blood less than 30 minutes

Old flu jabs from pandemic to combat this winter’s peak

Old flu jabs from pandemic to combat this winter’s peak

Extreme obesity a powerful risk factor for death among 2009 H1N1 patients

Extreme obesity a powerful risk factor for death among 2009 H1N1 patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.